Breakthrough combo targets aggressive stomach cancers
NCT ID NCT06206733
Summary
This large Phase 3 trial is testing whether adding an experimental drug called ASKB589 to standard chemotherapy and immunotherapy works better for people with advanced stomach or gastroesophageal cancer. The study involves 780 patients in China who have a specific biomarker called CLDN18.2. Researchers want to see if this new combination can help control the cancer longer and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing cancer hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.